NASDAQLPCN
Year
View
Form | Description | Date | Format |
---|---|---|---|
424B5 | Form of prospectus disclosing information facts events covered in both forms 424B2 424B3 | Apr 26, 2024 | ![]() ![]() ![]() ![]() |
S-3/A | Pre-effective amendment to an S-3 filing | Apr 23, 2024 | ![]() ![]() ![]() ![]() |
We are a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders. We improve compliance, absorption, and more with our proprietary drug delivery technology.
Form | Description | Date | Format |
---|---|---|---|
424B5 | Form of prospectus disclosing information facts events covered in both forms 424B2 424B3 | Apr 26, 2024 | ![]() ![]() ![]() ![]() |
S-3/A | Pre-effective amendment to an S-3 filing | Apr 23, 2024 | ![]() ![]() ![]() ![]() |